Braveheart Bio, Inc. (BRVE) company profile
BRVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 10, 2026
$18.78−0.71 (-3.64%)
Close on Nov 17, 2026Market cap $1.69BP/E –Yield –
About Braveheart Bio
Pharmaceutical Preparations, SIC 2834
Braveheart Bio, Inc. is listed on Nasdaq under the ticker BRVE, in the SEC industry Pharmaceutical Preparations. It is incorporated in Delaware and its fiscal year ends on December 31. Reported financials on StockData start in fiscal 2024.
Company profile
Company
- Legal name
- Braveheart Bio, Inc.
- Headquarters
- San Francisco, CA
- Address
- One Letterman Dr., Bldg. A, Ste. A4-300 94129
- Phone
- (415) 707-6312
- Website
- braveheart.bio
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
Stock & identifiers
- Ticker
- BRVE
- Exchange
- Nasdaq
- IPO date
- Aug 6, 2026
- Shares outstanding
- 90M, Sep 3, 2026
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 2131524
- CUSIP
- 10567X101
- ISIN
- US10567X1019
- FIGI
- BBG01YCFNLC2
- Share class FIGI
- BBG01YCFNLV1
- EIN
- 99-2981994
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Travis Murdoch | CEO and President, Director | 8,333,637 |
| Michele A. Anderson | Chief Development Officer | 332,161 |
| James Paul Rickey | Chief Financial Officer | 703,575 |
| Vineeta Agarwala | Director | 10,232,420 |
| Erez Chimovits | Director | 273,333 |
| Genesis GP LLC OrbiMed | Director | 273,333 |
| Capital GP IX LLC OrbiMed | Director | – |
| Advisors Llc Orbimed | Director | 1,102,739 |
| David Charles Lubner | Director | 55,555 |
| Jasper Bos | Director | – |
| Christopher Viehbacher | Director | 759,857 |
| Tim Lohoff | Director | – |
| David I. Malek | Director | 1,013,297 |
| Jason V. Coloma | Director | 1,100,456 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Aug 6, 2026
- Offer price
- $18.00
- Securities offered
- 21,250,000
- Gross proceeds
- $382.50M
- Exchange
- Nasdaq
- First trading day
- Aug 6, 2026
- First-day close
- $29.80+65.6%
- Lock-up ends (est.)
- Feb 2, 2027
“The initial public offering price per share is $18.00.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Aug 6, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?